Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial - Siu, L L; Even, C; Mesía, R (JAMA Oncol, 2019)
et al.